Peter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors

AdvaMed logo

December 11, 2023 | WASHINGTON, D.C.,  – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors.

“The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical time for medtech. Artificial Intelligence, imaging and digital technology represent important areas of innovation that can significantly accelerate diagnosis and improve the personalization of patient care. Peter’s proven record of leadership across more than three decades in medtech and imaging will enable him to advance AdvaMed’s goal of achieving healthier lives and healthier communities around the world. I look forward to working with him,” said AdvaMed President and CEO Scott Whitaker, who also serves as President of the AdvaMed Board of Directors.

Arduini said, “I appreciate the confidence my fellow AdvaMed Board members have placed in me as the Board’s new chair.  Through Scott’s leadership, AdvaMed has become a unifying voice for our industry to foster growth and innovative new solutions for patients, providers and health systems. The medical technology industry is at the forefront of defining the future of healthcare through smart devices, diagnostics and digital solutions that can enable earlier and more precise diagnoses, targeted treatments and improved patient outcomes. We need policies that keep pace with innovation, while fostering the highest ethical standards that improve patient access to the best care possible. With the promise of artificial intelligence and the interconnectivity of medical technologies, there has never been a more important time in our history to make profound and lasting changes in the delivery of care for patients.” 

Arduini has been president and chief executive officer of GE HealthCare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, since January 2022.  He previously served as president and chief executive officer of Integra LifeSciences Holdings Corporation, corporate vice president and president of Medication Delivery, Baxter Healthcare, from 2005 to 2010. He previously spent 15 years at GE Healthcare where in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Arduini also serves on the Boards of Directors of GE HealthCare, Bristol Myers Squibb and the National Italian American Foundation.

In the wake of former AdvaMed Chair Ashley McEvoy’s departure from Johnson & Johnson Medtech in October, Arduini stepped in to serve as interim chair over the past several weeks. The full Board elected him unanimously to a two-year term, which began immediately Friday.

Arduini  will unveil his priorities as AdvaMed Chair in early 2024.

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS